Katherine S. Pollard, PhD
Gladstone’s track record for creating and deploying new research technologies is phenomenal. From discovering how to reprogram cell fates to building the most sensitive mass spectrometry instruments in the world, our scientists are transforming what is possible in the lab. Novel mathematical models and informatics ensure that we mine as much knowledge as possible from our data. This spirit of innovation and knack for engineering is prevalent across our disease focused divisions. The goals of the Convergence Zone are to amplify this strength, to bring the best technology developers to Gladstone, and to share enabling platforms across labs.
Science has become much more collaborative in recent decades. The cross-fertilization of new ideas between laboratories often opens new research possibilities, and the combination of complementary skills accelerates progress. In addition to fruitful internal collaborations, our investigators maintain active, collaborative relationships with their scientific colleagues at other institutions. Most notably, we have a long-standing and successful affiliation with the University of California, San Francisco. Many Gladstone investigators also have active and beneficial partnerships with researchers at other universities and biotech and big pharma companies.
Our scientists discover new knowledge at a remarkable rate. All of these discoveries advance our understanding of how cells function, and some findings might lead to a “translatable asset.” Such assets can provide the starting point for a new medical product to prevent, ameliorate, or eradicate a serious disease. However, translatable assets cannot advance to cures without commercial investment from venture capitalists or biotechnology/pharmaceutical companies.
I am confident that our work will expand rapidly as we work with all of the investigators at Gladstone to accelerate our progress towards our goal of Science Overcoming Disease.